microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) have been extensively studied as potential biomarkers for Alzheimer's disease (AD). Their profiles have been analyzed in blood, cerebrospinal fluid (CSF) and brain tissue. However, due to the high variability between the reported data, stemming from the lack of methodological standardization and the heterogeneity of AD, the most promising miRNA biomarker candidates have not been selected. Our literature review shows that out of 137 miRNAs found to be altered in AD blood, 36 have been replicated in at least one independent study, and out of 166 miRNAs reported as differential in AD CSF, 13 have been repeatedly found. Only 3 miRNAs have been consistently reported as altered in three analyzed specimens: blood, CSF and the brain (hsa-miR-146a, hsa-miR-125b, hsa-miR-135a). Nonetheless, all 36 repeatedly differential miRNAs in AD blood are promising as components of the diagnostic panel. Given their predicted functions, such miRNA panel may report multiple pathways contributing to AD pathology, enabling the design of personalized therapies. In addition, the analysis revealed that the miRNAs dysregulated in AD overlap highly with miRNAs implicated in cancer. However, the directions of the miRNA changes are usually opposite in cancer and AD, indicative of an epigenetic trade-off between the two diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073
Bartel, D. P. (2018) · Cell · doi:10.1016/j.cell.2018.03.006 · Cited by 3,751
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805371200 · Cited by 441
Baggish, A. L., Hale, A., Weiner, R. B., Lewis, G. D., Systrom, D., Wang, F., Wang, T. J., & Chan, S. Y. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.213363 · Cited by 431
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study
Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., & Wolf, P. A. (2012) · BMJ · doi:10.1136/bmj.e1442 · Cited by 425
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
Sethi, P., & Lukiw, W. J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.04.052 · Cited by 409
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease
Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 347
Wang, W.-X., Huang, Q., Hu, Y., Stromberg, A. J., & Nelson, P. T. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0756-0 · Cited by 339
Lipid-based carriers of microRNAs and intercellular communication
Vickers, K. C., & Remaley, A. T. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328350a425 · Cited by 314
Cui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178848 · Cited by 274
MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130932 · Cited by 256
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M. G., Arighi, A., Fumagalli, G., & Scarpini, E. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140756 · Cited by 222
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Self-citationIs Alzheimer’s disease a systemic disease?
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.012 · Cited by 219
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
Amyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Developing novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease
Kumar, S., Vijayan, M., & Reddy, P. H. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx267 · Cited by 167
Riancho, J., Vázquez-Higuera, J. L., Pozueta, A., Lage, C., Kazimierczak, M., Bravo, M., Calero, M., Gonalezález, A., Rodríguez, E., Lleó, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161179 · Cited by 159
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156
Shafi, O. (2016) · BMC Neurology · doi:10.1186/s12883-016-0765-2 · Cited by 125
Association of cancer and Alzheimer's disease risk in a national cohort of veterans
Frain, L., Swanson, D., Cho, K., Gagnon, D., Lu, K. P., Betensky, R. A., & Driver, J. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.04.012 · Cited by 115
Downregulated serum miR‐223 servers as biomarker in Alzheimer's disease
Jia, L., & Liu, Y. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3184 · Cited by 95
Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA
Lukiw, W. J., Alexandrov, P. N., Zhao, Y., Hill, J. M., & Bhattacharjee, S. (2012) · NeuroReport · doi:10.1097/wnr.0b013e32835542b0 · Cited by 90
Differences in serum microRNA profiles in hepatitis B and C virus infection
Akamatsu, S., Hayes, C. N., Tsuge, M., Miki, D., Akiyama, R., Abe, H., Ochi, H., Hiraga, N., Imamura, M., Takahashi, S., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2014.10.017 · Cited by 64
Developments in Tau PET Imaging
Zimmer, E. R., Leuzy, A., Gauthier, S., & Rosa-Neto, P. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.15 · Cited by 60
Müller, M., Kuiperij, H. B., Versleijen, A. A. M., Chiasserini, D., Farotti, L., Baschieri, F., Parnetti, L., Struyfs, H., De Roeck, N., Luyckx, J., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160038 · Cited by 41
van Harten, A. C., Mulders, J., Scheltens, P., van der Flier, W. M., & Oudejans, C. B. M. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140075 · Cited by 41
Bialopiotrowicz, E., Kuzniewska, B., Kachamakova-Trojanowska, N., Barcikowska, M., Kuznicki, J., & Wojda, U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.017 · Cited by 32
Self-citation
Cited by
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
“The involvement of miRNAs in the pathogenesis of AD, the ability to detect them in easily accessible body fluids and the relatively high stability of miRNAs compared to mRNA make them an attractive target for AD biomarker discovery [42, 141, 142].”
BackgroundGarcía-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Dong, Z., Gu, H., Guo, Q., Liang, S., Xue, J., Yao, F., Liu, X., Li, F., Liu, H., Sun, L., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02323-y · Cited by 101
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer
Godlewski, J., Lenart, J., & Salinska, E. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010020 · Cited by 52
Prieto-Fernández, E., Aransay, A. M., Royo, F., González, E., Lozano, J. J., Santos-Zorrozua, B., Macias-Camara, N., González, M., Garay, R. P., Benito, J., et al. (2019) · Theranostics · doi:10.7150/thno.31502 · Cited by 28
Metadata
- Authors
- Nagaraj, S., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 49
- Pages
- 125-143
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W2898991528
- Cited by
- 121
- References
- 51
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.